Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 154

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 154
---

  
    (2)
    Member
    of the Compensation Committee
  
    (3)
    Member
    of the Nominating and Corporate Governance Committee

*Timothy
Lorber assumed the position of Chief Financial Officer on a part-time basis commencing June 13, 2024 and assumed the full-time position
of Chief Financial Officer on September 9, 2024. Prior to June 13, 2024, Michael Vander Hoek served as our Chief Financial Officer.

Set
forth below is a description of the background and business experience of our directors and executive officers.

Anatoly
Dritschilo, M.D. Dr. Dritschilo is a co-founder of the Company and has served as Chief Executive Officer and Chairman of the Board
of Directors since the Company’s formation in December 2012. Dr. Dritschilo is a radiation oncologist by training and has held
multiple leadership positions in health care. At Georgetown University Medical School in Washington, D.C., he served principally as Department
Chair from 1980 to 2022; Chief of Radiation Oncology at MedStar-Georgetown University Hospital from 2005 to 2022; Medical Director of
Georgetown University Hospital from 1994 to 1997; and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005
to 2007. He has also served on the boards of directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation
Hospital, and the MedStar Health Research Institute. Previously, he was a founding director of Oncomed, Inc. and a member of the board
of directors of Neopharm, Inc. His 250+ scientific publications and 12 issued patents have earned him election as a Fellow of the National
Academy of Inventors. Dr. Dritschilo holds a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania,
a medical degree from the College of Medicine of New Jersey and residency training from the Harvard Joint Center for Radiation Therapy.
His qualifications support his service as our Chief Executive Officer and Chairman of the Board of Directors.

Timothy
J. Lorber, CPA serves as the Company’s Chief Financial Officer, a position he assumed on a part-time basis commencing June
13, 2024 and assumed the full-time position of Chief Financial Officer on September 9, 2024. Mr. Lorber has more than 40 years of professional
finance experience, including Leg